UK-based GlaxoSmithKline is one of the world's leading pharmaceutical research companies. The company was created out of the merger between GlaxoWellcome and SmithKline Beecham in 2000.
Glaxosmithkline Plc Ord 25P is listed on the London Stock Exchange trading with ticker code GSK.L, and is part of the Medicine and Biotech Research sector. It has a market capitalisation of £7,514,264m, with approximately 4,919m shares in issue. Over the last year, Glaxosmithkline Plc share price has been traded in a range of 130, hitting a high of 734.00, and a low of 604.00.
Glaxosmithkline Plc, officially known as Glaxosmithkline Plc Ord 25P was formed in December of 1999, making the company twenty years old. The company filed its latest accounts on 31st December 2014, showing a turnover of approximately 23.01 billion GBX with gross profits of 15.68 billion, or 3.1882 per issued share, and a pre-tax profit margin of 12.9%. Glaxosmithkline Plc currently has 14 directors, and has had 33 previous directors over the last 20 years. In the last set of accounts produced by Pricewaterhousecoopers Llp, the company showed 7.52 billion paid in salaries to the 98,702 staff (average wage of 76 thousand), with the directors receiving an average 830.50 million each. In the accounts filed in 2014, the company paid 3843000000 in dividends, or 0.7813 per share.
Glaxosmithkline Plc is in the Medicine and Biotech Research sector.
|British American Tobacco Plc (BATS.L)|
|Royal Dutch Shell Plc 'B' (RDSB.L)|
|Royal Dutch Shell Plc 'A' (RDSA.L)|
|Hikma Pharmaceuticals Plc (HIK.L)|
|Shares in Issue||4,919m|
|52 Week High||734.00|
|52 Week Low||604.00|
GSK Plc. is an avoid at the current levels as the stock has been in correction mode for quite some time. The company announced its results on 26th July and investor sentiments surely look dampened post the results as the stock continued its southward journey after the announcement of the results. The stock finished trading on the London Stock exchange at 1514.0p a share on Monday, 31st July. The stock has been nonstop falling post the announcement of its results. Therefore, traders or investors are advised to stay away from the stock at least for the time being. In terms of charting or technical analysis also, the stock has made rounding top pattern which further confirms the bearish pattern of the stock and we expect the bearish trend to continue for the short term and see no signs of reversal anytime soon. The momentum oscillators like RSI and MACD also indicates the same. The stock has also been trading below its 20 day moving average (DMA), 50 DMA and 100 DMA of 1594.0p, 1644.0p and 1640p respectively. The weekly charts also indicates double top pattern which again is a confirmation of bearish trend. Thus, GSK Plc. is an avoid for sure for the time being. (Read more)
GlaxoSmithKline Plc. is a compelling buy at the current levels. The stock has been rallying for quite some time now and we anticipate this rally to continue. The stock finished trading on the London Stock exchange at 1654 p a share on Tuesday, 21st February. Currently, the stock has been trading above its 20 day moving average, 50 DMA and 100 DMA of 1569p, 1556p and 1571p respectively. The stock has been trading 6% below its 52 weeks high and 21% above its 52 weeks low. In terms of technical indicators also, the stock has been making higher highs and lower lows and have been trading on the upward trend line. We see Stock going towards 1720 p in a short term only and stock might have resistance at 1720 p. The immediate support for the stock is at 1575p and it’s pretty unlikely that the stock would go below 1575p. Therefore, any dip in GSK PLC is nothing but a lucrative opportunity to buy or built fresh long positions. The RSI indicator also states that the stock shall continue to rally for some time. (Read more)
Glaxosmith kline Plc is a hold at the current price levels as we see an upside of up to 6% from the current levels. The company announced its half yearly 2016 results on 27th July 2016 and the impact of the results on stock was also neutral. However, the stock has been correcting since the last few sessions and has come down from 1714p to 1612p lately. We see this dip in the stock as an opportunity to buy the stock as considering the fundamentals and financial matrix of the company, Glaxosmith kline Plc is surely a value buy. (Read more)